FREE SHIPPING ON ORDERS OVER $200 Now testing for heavy metals and endotoxins ≥98.5% purity Third-party HPLC tested COA on every batch Fast, discreet US shipping
Epitalon 10mg research peptide vial
Growth & Longevity

Epitalon

Epithalon (AEDG)

A tetrapeptide studied in telomerase and circadian-regulation research.

From $75

In stock · ships in 1–2 business days

  • ✓ 99.76% purity (tested)
  • ✓ HPLC + mass-spec tested
  • ✓ View batch COA
  • ✓ Discreet US shipping
longevity researchtelomere

Research Summary

Epitalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) studied in preclinical research for its role in telomerase activity and pineal/circadian regulation models. For laboratory research use only.

Handling

Store the sealed lyophilized peptide at -20°C, protected from light and moisture. Let the vial reach room temperature before opening to limit condensation. Any further handling should follow your laboratory's own validated procedures, using appropriate protective equipment.

Research overview

Epitalon: what the research shows

Reviewed October 12, 2026 against PubMed and primary sources. For research context only, not medical advice.

What is Epitalon?

Epitalon, also spelled Epithalon, is the synthetic tetrapeptide Ala-Glu-Asp-Gly, often abbreviated AEDG [1]. It was designed from the amino acid composition of epithalamin, a polypeptide extract of bovine pineal gland, before the tetrapeptide itself had been found in pineal tissue [2]. In 2017 the originating group reported detecting AEDG among the tetrapeptides of a pineal polypeptide complex using mass spectrometry and HPLC [3].

A 2025 review from the University of Warsaw summarized roughly 25 years of in vitro, in vivo, and in silico work. It listed reported effects on melatonin synthesis, interleukin-2 mRNA, thymocyte mitogenic activity, and the activity of enzymes including acetylcholinesterase and telomerase, while stating that it remains uncertain whether these are its only mechanisms. The review also noted that physical-chemical and structural studies of the peptide are quite limited [2].

Epitalon molecular identity
SequenceAla-Glu-Asp-Gly (AEDG)
Length4 amino acids (tetrapeptide)
Molecular formulaC14H22N4O9
Molecular weight390.35 g/mol
CAS number307297-39-8
PubChem CID219042
Other namesEpithalon, Epithalone, AEDG peptide (PubChem synonyms)

Where the research comes from

Readers should know one thing before weighing this literature: most published Epitalon research comes from a single research network in St. Petersburg, Russia, centered on Khavinson and colleagues at the Saint Petersburg Institute of Bioregulation and Gerontology, together with collaborators such as Anisimov's group at the city's oncology institute [4] [7] [9].

Independent work does exist but is limited. Examples include a 2022 oocyte study from researchers in China and the United States [8], a 2025 telomere study from Brunel University London [5], and the 2025 Warsaw review [2]. Concentration of evidence in one group does not make findings wrong, but it does mean most results have not been independently replicated.

Mechanisms studied

Telomerase and telomere length

In a short 2003 report, the St. Petersburg group added Epitalon to cultures of telomerase-negative human fetal fibroblasts and reported expression of the telomerase catalytic subunit, telomerase enzyme activity, and telomere elongation [4].

A 2025 study from an independent UK laboratory revisited this question in more detail. In normal human epithelial and fibroblast cells, Epitalon produced concentration-dependent telomere lengthening through increased hTERT mRNA expression and telomerase activity. In the breast cancer cell lines 21NT and BT474, telomeres also lengthened, but mainly through activation of ALT (alternative lengthening of telomeres), a telomerase-independent pathway; only a minor ALT increase was seen in normal cells [5]. The cancer-cell finding is relevant to anyone interpreting telomere data from this compound.

Pineal signaling

In a 2002 rat study, Epitalon modulated pineal activity, measured by c-Fos protein in pinealocytes, only in animals under osmotic stress and not in unstressed animals, and it partially reduced stress-related changes in the pineal parenchyma [6].

Gene expression and chromatin

In human gingival mesenchymal stem cells, AEDG increased synthesis and mRNA expression of the neurogenic markers Nestin, GAP43, beta-III tubulin, and doublecortin. Molecular modeling in the same paper suggested the peptide binds linker histones H1/3 and H1/6, which the authors proposed as an epigenetic mechanism [7]. The histone binding was a computational prediction, not a direct measurement.

Areas of research

Cell models

In mouse oocytes aged in culture after ovulation, Epitalon in the culture medium reduced intracellular reactive oxygen species, lowered the frequency of spindle defects and abnormal cortical granule distribution, increased mitochondrial membrane potential and mitochondrial DNA copy number, and reduced apoptosis by 24 hours [8].

Rodent studies of aging biomarkers and tumors

In a 2003 study of female outbred SHR mice followed from 3 months of age until natural death, Epitalon did not change food consumption, body weight, mean life span, or total spontaneous tumor incidence. The authors reported a slower age-related decline of estrous function, fewer chromosome aberrations in bone marrow cells, longer survival of the last 10% of animals, and fewer leukemias than in controls [9]. In HER-2/neu transgenic mice, which develop spontaneous mammary tumors, Epitalon was associated with a lower cumulative number and smaller maximum size of tumors and reduced HER-2/neu mRNA in tumor tissue [10].

Invertebrate model

In a 2000 study in Drosophila melanogaster, adding Epitalon to the culture medium only during development (egg to larva) was associated with an 11 to 16% longer adult fly life span compared with controls [11].

Open research questions

  • Independent replication of the rodent findings outside the originating network.
  • Whether telomere effects differ between normal and transformed cells, as the 2025 ALT data suggest [5].
  • Basic structural and physical-chemical characterization, which the 2025 review described as limited [2].

State of the human evidence

Controlled human data on Epitalon are essentially absent. A PubMed search for clinical-trial publication types on the review date returned one record: a 2002 report of clinical observations from the originating group [12]. The abstract does not describe a randomized or placebo-controlled design, and no independent replication has been published. FDA's 2026 compounding safety-risk page states that the agency did not identify safety information for the proposed route and lacks sufficient information to judge potential harm [14].

A 2015 Belgian public-health laboratory report also documented Epitalon in two illegal pharmaceutical preparations, an example of the compound circulating outside regulated channels [13]. Findings in cell, fly, and rodent models should not be read as evidence of safety or benefit in people.

Regulatory status

  • Not FDA approved. Epitalon is not an FDA-approved drug. FDA's list of bulk drug substances that may present significant safety risks (content current as of April 22, 2026) shows epitalon among substances whose nominations were withdrawn, noting a possible immunogenicity risk for certain routes due to the potential for aggregation, and peptide-related impurities [14].
  • Advisory committee vote. On July 24, 2026, FDA's Pharmacy Compounding Advisory Committee voted to recommend epitalon for the 503A bulks list [15]. The committee's votes are recommendations and are not binding on FDA, and pharmacies may not compound a substance on that basis until final rulemaking is in place [16]. FDA had not completed any such action at the time of this review.
  • Sport. Epitalon is not named on the World Anti-Doping Agency's 2026 Prohibited List. WADA's S0 class covers pharmacological substances with no current government approval for human therapeutic use, and WADA advises checking with an anti-doping organization about unlisted substances [17].

Rejuvatide supplies Epitalon strictly as a research chemical for in vitro and laboratory use. It is not sold for human or veterinary use.

Testing and quality

Every Rejuvatide lot of Epitalon is tested by an independent laboratory for purity by HPLC and identity by LC-MS, and the lot also carries an endotoxin certificate. The current certificates are shown below and in our COA library, where you can match the lot number on your vial to its report. Certificates are published exactly as the laboratory issued them.

Another short peptide in our catalog is Pinealon. Browse all growth-axis research compounds, or see our FAQ for ordering questions.

Storage of lyophilized material

Epitalon ships as a lyophilized (freeze-dried) powder. For long-term storage, keep sealed vials at -20°C, protected from light and moisture. Allow a vial to reach room temperature before opening to limit condensation. Handling of any prepared solutions should follow your laboratory's own validated procedures.

Certificate of Analysis

Independently tested by Freedom Diagnostics. This is the certificate for the current batch of Epitalon.

99.76%HPLC purity
Lot 60730-12Tested batch

Your browser cannot display the PDF inline. Open the Certificate of Analysis.

Epitalon FAQ

What is Epitalon?

Epitalon (Epithalon, AEDG) is the synthetic tetrapeptide Ala-Glu-Asp-Gly, designed from the composition of a bovine pineal extract. It is studied in preclinical telomerase, pineal-signaling, and gene-expression research.

Who has studied Epitalon?

Most published work comes from one research network in St. Petersburg, Russia, centered on the Saint Petersburg Institute of Bioregulation and Gerontology. Independent studies are few.

Does Epitalon activate telomerase?

In cell culture, the originating group reported telomerase activation in human fibroblasts, and a 2025 UK study reported telomerase-driven telomere lengthening in normal cells but ALT-driven lengthening in breast cancer cell lines. There is no controlled human evidence.

Is Epitalon FDA approved?

No. An FDA advisory committee voted in July 2026 to recommend epitalon for the 503A compounding bulks list, but that vote is non-binding and does not make it an approved drug.

What sizes of Epitalon does Rejuvatide offer?

Epitalon is available in 10mg, 30mg, and 50mg vials of lyophilized powder.

How is Rejuvatide Epitalon tested?

Each lot is tested by an independent laboratory for HPLC purity and LC-MS identity, with a separate endotoxin certificate, published in the COA library and matched to the lot number on the vial.

Is Epitalon for human use?

No. Rejuvatide sells Epitalon for laboratory research use only. It is not for human or veterinary use, and nothing on this site is medical advice.

References

  1. PubChem. Epitalon, Compound CID 219042. National Library of Medicine. Source
  2. Araj SK, Brzezik J, Mądra-Gackowska K, et al. Int J Mol Sci. 2025;26(6). PubMed 40141333
  3. Khavinson VK, Kopylov AT, Vaskovsky BV, et al. Bull Exp Biol Med. 2017;164(1):41-43. PubMed 29124531
  4. Khavinson VKh, Bondarev IE, Butyugov AA. Bull Exp Biol Med. 2003;135(6):590-2. PubMed 12937682
  5. Al-Dulaimi S, Thomas R, Matta S, et al. Biogerontology. 2025;26(5):178. PubMed 40908429
  6. Sibarov DA, Kovalenko RI, Malinin VV, et al. Neuro Endocrinol Lett. 2002;23(5-6):452-4. PubMed 12500171
  7. Khavinson V, Diomede F, Mironova E, et al. Molecules. 2020;25(3). PubMed 32019204
  8. Yue X, Liu SL, Guo JN, et al. Aging (Albany NY). 2022;14(7):3191-3202. PubMed 35413689
  9. Anisimov VN, Khavinson VKh, Popovich IG, et al. Biogerontology. 2003;4(4):193-202. PubMed 14501183
  10. Anisimov VN, Khavinson VK, Provinciali M, et al. Int J Cancer. 2002;101(1):7-10. PubMed 12209581
  11. Khavinson VK, Izmaylov DM, Obukhova LK, et al. Mech Ageing Dev. 2000;120(1-3):141-9. PubMed 11087911
  12. Khavinson V, Razumovsky M, Trofimova S, et al. Neuro Endocrinol Lett. 2002;23(4):365-8. PubMed 12195242
  13. Vanhee C, Moens G, Van Hoeck E, et al. Drug Test Anal. 2015;7(3):259-64. PubMed 25535022
  14. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). Source
  15. Regulatory Affairs Professionals Society. FDA advisory committee backs two more peptides, rejects one for compounding list (July 24, 2026). Source
  16. National Community Pharmacists Association. FDA advisory committee nominates six peptides for pharmacies to compound (July 31, 2026). Source
  17. World Anti-Doping Agency. The 2026 Prohibited List, S0 Non-Approved Substances. Source